These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29780867)

  • 1. Topographic staging of tau positron emission tomography images.
    Schwarz AJ; Shcherbinin S; Slieker LJ; Risacher SL; Charil A; Irizarry MC; Fleisher AS; Southekal S; Joshi AD; Devous MD; Miller BB; Saykin AJ;
    Alzheimers Dement (Amst); 2018; 10():221-231. PubMed ID: 29780867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
    Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
    Soleimani-Meigooni DN; Iaccarino L; La Joie R; Baker S; Bourakova V; Boxer AL; Edwards L; Eser R; Gorno-Tempini ML; Jagust WJ; Janabi M; Kramer JH; Lesman-Segev OH; Mellinger T; Miller BL; Pham J; Rosen HJ; Spina S; Seeley WW; Strom A; Grinberg LT; Rabinovici GD
    Brain; 2020 Dec; 143(11):3477-3494. PubMed ID: 33141172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between quantitative [
    Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM
    Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [
    Young CB; Landau SM; Harrison TM; Poston KL; Mormino EC;
    Neuroimage; 2021 Nov; 243():118553. PubMed ID: 34487825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.
    Devous MD; Joshi AD; Navitsky M; Southekal S; Pontecorvo MJ; Shen H; Lu M; Shankle WR; Seibyl JP; Marek K; Mintun MA
    J Nucl Med; 2018 Jun; 59(6):937-943. PubMed ID: 29284675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional [
    Wolters EE; Ossenkoppele R; Verfaillie SCJ; Coomans EM; Timmers T; Visser D; Tuncel H; Golla SSV; Windhorst AD; Boellaard R; van der Flier WM; Teunissen CE; Scheltens P; van Berckel BNM
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2866-2878. PubMed ID: 32291510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PET.
    Hong J; Kang SK; Alberts I; Lu J; Sznitman R; Lee JS; Rominger A; Choi H; Shi K;
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3061-3072. PubMed ID: 35226120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
    Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
    JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study.
    Chen SD; Lu JY; Li HQ; Yang YX; Jiang JH; Cui M; Zuo CT; Tan L; Dong Q; Yu JT;
    Transl Psychiatry; 2021 Sep; 11(1):483. PubMed ID: 34537810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging.
    Marquié M; Siao Tick Chong M; Antón-Fernández A; Verwer EE; Sáez-Calveras N; Meltzer AC; Ramanan P; Amaral AC; Gonzalez J; Normandin MD; Frosch MP; Gómez-Isla T
    Acta Neuropathol; 2017 Oct; 134(4):619-628. PubMed ID: 28612291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles.
    Pascoal TA; Therriault J; Benedet AL; Savard M; Lussier FZ; Chamoun M; Tissot C; Qureshi MNI; Kang MS; Mathotaarachchi S; Stevenson J; Hopewell R; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2020 Sep; 143(9):2818-2830. PubMed ID: 32671408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity.
    Southekal S; Devous MD; Kennedy I; Navitsky M; Lu M; Joshi AD; Pontecorvo MJ; Mintun MA
    J Nucl Med; 2018 Jun; 59(6):944-951. PubMed ID: 29191858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [
    Risacher SL; Farlow MR; Bateman DR; Epperson F; Tallman EF; Richardson R; Murrell JR; Unverzagt FW; Apostolova LG; Bonnin JM; Ghetti B; Saykin AJ
    Acta Neuropathol Commun; 2018 Oct; 6(1):114. PubMed ID: 30373672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Criterion Validation of Tau PET Staging Schemes in Relation to Cognitive Outcomes.
    Hammers DB; Lin JH; Polsinelli AJ; Logan PE; Risacher SL; Schwarz AJ; Apostolova LG;
    J Alzheimers Dis; 2023; 96(1):197-214. PubMed ID: 37742649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau PET With
    Huang CC; Hsiao IT; Huang CY; Weng YC; Huang KL; Liu CH; Chang TY; Wu HC; Yen TC; Lin KJ
    Front Neurol; 2019; 10():503. PubMed ID: 31191427
    [No Abstract]   [Full Text] [Related]  

  • 20. In vivo tau pathology is associated with synaptic loss and altered synaptic function.
    Coomans EM; Schoonhoven DN; Tuncel H; Verfaillie SCJ; Wolters EE; Boellaard R; Ossenkoppele R; den Braber A; Scheper W; Schober P; Sweeney SP; Ryan JM; Schuit RC; Windhorst AD; Barkhof F; Scheltens P; Golla SSV; Hillebrand A; Gouw AA; van Berckel BNM
    Alzheimers Res Ther; 2021 Feb; 13(1):35. PubMed ID: 33546722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.